SCHEMBL1607491

SCHEMBL1607491

CC(C)n1nnc2cc(-c3cc(-c4ccc(N(C)C)cc4)[nH]n3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.41
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
APP P05067 1/20 0.41
RAB9A P51151 4/20 0.36
MAPT P10636 3/20 0.36
NPC1 O15118 2/20 0.36
MAPK1 P28482 2/20 0.36
TNIK Q9UKE5 2/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
ALPG P10696 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
GSK3A P49840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1607642 0.74 RAB9A (0.43) HPGDAPPRAB9AMAPTNPC1
SCHEMBL1608493 0.73 APP (0.46) APPRAB9AMAPTNPC1MAPK1
SCHEMBL1608226 0.71 KDM1A (0.46) APPRAB9AMAPTNPC1MAPK1
SCHEMBL1250263 0.71 APP (0.46) APPRAB9AMAPTNPC1MAPK1
SCHEMBL1249681 0.69 TNIK (0.55) APPRAB9AMAPTNPC1MAPK1
SCHEMBL1251703 0.69 APP (0.52) APPRAB9AMAPTNPC1MAPK1
SCHEMBL12573247 0.69 APP (0.52) APPRAB9AMAPTNPC1MAPK1
SCHEMBL23524262 0.69 HCAR3 (0.47) HPGDHCAR3HCAR2ALDH1A1CDK1
SCHEMBL1608233 0.69 APP (0.44) APPRAB9AMAPTNPC1MAPK1
SCHEMBL1608248 0.68 APP (0.46) APPRAB9AMAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 HPGD 1371/4885HCAR3 560/4885HCAR2 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.